Transactions
12
Insider / LABCORP HOLDINGS INC.
van der Vaart Sandra D
EVP, Corporate Affairs at LABCORP HOLDINGS INC.
- Company
- LABCORP HOLDINGS INC.
- Ticker
- LH
- First filing on record
- February 10, 2026
- Latest trade on record
- March 26, 2026
- SEC filings
- EDGAR ↗
van der Vaart Sandra D, EVP, Corporate Affairs at LABCORP HOLDINGS INC., has disclosed 12 transactions in LH since February 10, 2026: 0 purchases (0 open-market buys) and 5 sales, worth about $969K at the reported prices. The latest was filed March 30, 2026, 4 days after the trade.
Open-market buys
0
Sales
5
Avg. disclosure lag
3.1d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months van der Vaart Sandra D made no purchases and 5 sales worth $969K, plus 7 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
van der Vaart Sandra D has traded 1 stock on record; the largest by dollars is LH.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 4 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 6 | 2,232 | — |
| F | Shares withheld for tax | 4 | 3,015 | $813K |
| A | Grant or award | 1 | 6,382 | — |
| S | Open-market sale | 1 | 548 | $156K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 12 | 0 | 5 · $969K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| LH | Sell F | March 26, 2026 | March 30, 2026 | 4d | 2,722 | $268 | $731K | Form 4 ↗ | ||
| LH | Other A | March 26, 2026 | March 30, 2026 | 4d | 6,382 | — | — | Form 4 ↗ | ||
| LH | Sell S | February 27, 2026 | March 3, 2026 | 4d | 548 | $285 | $156K | Form 4 ↗ | ||
| LH | Option / conversion M | February 11, 2026 | February 13, 2026 | 2d | 376 | — | — | derivative | Form 4 ↗ | |
| LH | Sell F | February 11, 2026 | February 13, 2026 | 2d | 99 | $290 | $29K | Form 4 ↗ | ||
| LH | Option / conversion M | February 11, 2026 | February 13, 2026 | 2d | 376 | — | — | Form 4 ↗ | ||
| LH | Option / conversion M | February 7, 2026 | February 10, 2026 | 3d | 353 | — | — | derivative | Form 4 ↗ | |
| LH | Option / conversion M | February 6, 2026 | February 10, 2026 | 4d | 387 | — | — | derivative | Form 4 ↗ | |
| LH | Sell F | February 9, 2026 | February 10, 2026 | 1d | 93 | $274 | $25K | Form 4 ↗ | ||
| LH | Option / conversion M | February 7, 2026 | February 10, 2026 | 3d | 353 | — | — | Form 4 ↗ | ||
| LH | Sell F | February 6, 2026 | February 10, 2026 | 4d | 101 | $277 | $28K | Form 4 ↗ | ||
| LH | Option / conversion M | February 6, 2026 | February 10, 2026 | 4d | 387 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| March 30, 2026 | Form 4 | 0000920148-26-000120 | 2 | published | EDGAR ↗ |
| March 3, 2026 | Form 4 | 0000920148-26-000113 | 1 | published | EDGAR ↗ |
| February 13, 2026 | Form 4 | 0000920148-26-000088 | 3 | published | EDGAR ↗ |
| February 10, 2026 | Form 4 | 0000920148-26-000028 | 6 | published | EDGAR ↗ |
Other insiders at LABCORP HOLDINGS INC.
- Wengel Kathryn E EVP, Chief TO and Risk Officer 24 rows
- Schechter Adam H Director 22 rows
- Wilkinson Peter J SVP, Chief Accounting Officer 22 rows
- Caveney Brian J EVP, Pres of ED, CMO & CSO 20 rows
- Bailey Megan D. EVP, Pres, Central Labs & Intl 19 rows
- Kyle Kathryn W EVP, Chief Legal Officer 18 rows
- Meltzer Jonathan C EVP, Operations 18 rows
- Vaughn Bryan T EVP, Diagnostics 18 rows
- Oyegunwa Akinbolade EVP, CIO & CTO 17 rows
- Schroeder Mark S EVP, Pres Diagnostics & COO 16 rows
Everyone on file, with contracts and lobbying under the company's name: LABCORP HOLDINGS INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 12 | February 10, 2026 | March 30, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.